Urology Board Reviews

The BoardVitals Urology CME Review offers clinicians 40 AMA PRA Category 1 Credits^TM and over 700 Urology board review questions. The questions cover key topics including bladder cancer, bladder dysfunction, and infertility. This question bank will assist clinicians with Urology certification and recertification.

The BoardVitals Urology CME Review also features:

• Quick and Convenient CME
• Computer, phone, and tablet access
• Constantly updated up-to-date questions
• Questions that are targeted specifically to the exam
• Online CME tracker
• 100% Pass Guarantee
• Statistical comparison to other Urology test-takers (Nationally)

After completing this activity, you should be able to:

• Diagnose common and rare disorders which may be encountered in Urology.
• Order and interpret results of common laboratory tests in Urology.
• Describe the range of available treatments and essential concepts in the field of Urology

Target Audience: Urologists

Urology CME: Diagnostic Approaches, Therapeutic Advances

Comprehensive Review of Urology provides current, relevant information on adult and pediatric disorders of the male and female urinary tract, the male reproductive system, and the kidney. Led by renowned urologist Aria F. Olumi, MD, lecturers use guideline-driven information that will improve your approach to screening, staging, diagnosis, and treatment. You’ll get expert take-home points from each continuing medical education lecture, including:

• MRI of Prostate Cancer. MRI is effective in detecting focal areas of highgrade prostate cancer, providing accurate locoregional staging, and guiding targeted biopsies.
• Kidney Cancer – Laparoscopic Management. Laparoscopic and robotic nephrectomy is now the standard care for most renal cell carcinoma patients. It offers significant advantages in morbidity while maintaining oncologic outcomes of open surgery.
• The Etiology and Treatment of Pelvic Organ Prolapse. Vaginal wall descent is a normal part of aging; however, once the bulge protrudes past the hymen, most women are symptomatic.
• Advances in Systemic Therapy for Management of Muscle Invasive Bladder Cancer. Neoadjuvant chemotherapy remains the standard of care for muscle-invasive bladder cancer.
• And many more!